Investor Presentation Q4 2018
TSXv: NDVA 2/22 I N V E S T O R P R E S E N TAT I O N The information contained herein, together with any amendments or supplements and any other information that may be furnished by the company, includes forward-looking information. Such information is based on assumptions as to future events that are inherently uncertain and subjective. The company makes no representation or warranty as to the attainability of such Forward assumptions, including the completion of a fjnancing or as to whether future results will occur as projected. Looking It must be recognized that the projections of the Statement company’s future performance are necessarily subject to a high degree of uncertainty, that actual results can be expected to vary from the results projected and that such variances may be material and adverse. Prospective investors are expected to conduct their own investigation with regard to the company and its prospects. This presentation does not constitute an ofger to sell or a solicitation of an ofger to buy any security.
TSXv: NDVA 3/22 I N V E S T O R P R E S E N TAT I O N 01 – Executive Summary _________________________________________ 4 SUMMARY Growing Demand for Medical Cannabis _______________________ 6 02 – Recreational Cannabis Market ________________________________ 7 INVESTING IN CANNABIS Supply of Cannabis __________________________________________ 8 Table of Talented and Experienced Team ______________________________ 10 High Quality Products _______________________________________ 11 03 – Contents INDIVA ADVANTAGES Our Corporate Identity ______________________________________ 14 Customer Acquisition Strategies ______________________________ 15 London Facility _____________________________________________ 17 04 – Production Facility Pictures __________________________________ 19 LONDON FACILITY Expansion Path - Flowers, Oil, Products ________________________ 20 05 – London Operating Expenses __________________________________ 22 COST BREAKDOWN
TSXv: NDVA 4/22 I N V E S T O R P R E S E N TAT I O N NEAR TERM CATALYSTS Sales Expansion Processing Facility Executive Cultivation and oil INDIVA received Fully funded processing extraction: Fully funded its sales license on facility planned for 2019. Summary expansion to 40,000 square August 10, 2018 and Facility to produce INDIVA, feet underway and to be sales have begun. Bhang, DeepCell and completed in Q1 of 2019. other cannabis products. Capitalization: Basic Shares Outstanding ............................ 83.0mm STRONG FUNDAMENTALS Warrants: .............................. 28.3mm Options: .................................... 4.7mm • Award-winning cannabis products Convert: ................................... 6.9mm Fully Diluted Shares • State-of-the-art GMP-standard indoor Outstanding .......................... 122.9mm production facility Balance Sheet: • Fully funded expansion Cash (Sept. 30, 2018) ..... $24.3mm • Experienced Master Grower with award- Management and winning strains and loyal 1000+ patient base Insider Ownership ...................... 22% • Experienced management team, passionate about helping people and protecting investors
Investing in INDIVA London Cost Executive Cannabis Advantages Facility Breakdown Summary 01 02 03 04 05 02 Investing in Q4 2018 Cannabis
TSXv: NDVA 6/22 I N V E S T O R P R E S E N TAT I O N Health Canada’s Projected Registered Patients Actual Registered Patients 450,000 400,000 Registered Patients June 2018: registered 350,000 patients exceeds Health 300,000 Canada’s 2023 projection 250,000 200,000 150,000 Growing 100,000 50,000 Demand 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 for Medical GROWTH RATE OF MEDICINAL CANNABIS USERS IS HIGHER THAN EXPECTED Cannabis Health Canada projected 450,000 patients will be using cannabis at $1.3 billion annual 16,599 revenue by 2024. physicians have authorized patient access to medicinal marijuana 6,000,000 5,000,000 330,758 4,000,000 registered patients 3,000,000 in total to date 2,000,000 (~80% from ON and AB) 1,000,000 Multiple Risk of Migraine Life Stress Sclerosis Epilepsy Cancer Low BMI Severe Pain Depression Headaches Insomnia Anxiety Arthritis Hypertension (Elevated) 10,000 (approx.) new patients per month POTENTIAL MARKET Source: Health Canada, Statistics Canada, Canadian Community Health Survey, medicalmarijuana.ca
TSXv: NDVA 7/22 I N V E S T O R P R E S E N TAT I O N Daily Weekly Monthly Occasionally Non-Consumers Potential Customer 7% 4% 17% SIZE AND MAKEUP OF THE CANADIAN 3% RECREATIONAL MARKET 8% According to the Deloitte Survey, the size of the Canadian recreational cannabis market could be as much as $8.7 billion per year, or similar to the size of the Canadian Recreational spirit market. 61% Cannabis Source: Deloitte, PBO Users (Thousands) Consumption (Metric Tonnes) $7-10 Billion Domestic Market 1600 1200 Opportunity! 375 800 600 * 2.6 million Canadians admit to use in last 250 12 months 200 * Represents <5% of total consumption 20 10 Once Less than once a month 1-3 Times per month At least once a week Daily ANNUAL CANNABIS USERS Aged 15 and over, Canada excluding Territories, Mid-point Estimates, 2018 AND CONSUMPTION
TSXv: NDVA 8/22 I N V E S T O R P R E S E N TAT I O N Number of licences issued YT 0 by province NU NT 0 0 NL 0 Supply of BC 30 AB Cannabis MB QC 9 2 12 PE SK 1 ON 4 69 OVER-supply NS 3 of dry fmower NB 3 just around the corner! Licensed Producer Production Capacity Tonnes Aurora Cannabis ............................................... 700 Canopy Growth ............................................... 500 Aphria ............................................... 255 Tilray ............................................... 200 The Green Organic Dutchman .................................................. 95 Cronos Group ................................................. 135 OrganiGram .................................................. 113 HEXO ................................................ 108 Current Production CannTrust ................................................ 105 • 132 existing LPs Emerald Health Therapeutics ................................................ 100 • Current production insuffjcient – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – TOTAL (metric tonnes) ............................................ 2,411 to meet demand • 70 Sales Licenses issued Source: Mackie Research, 420intel.com
Investing in INDIVA London Cost Executive Cannabis Advantages Facility Breakdown Summary 01 02 03 04 05 03 INDIVA Q4 2018 Advantages
Recommend
More recommend
